Nicholson Wealth Management Group LLC Makes New Investment in Perspective Therapeutics, Inc. (NYSE:CATX)

Nicholson Wealth Management Group LLC bought a new position in Perspective Therapeutics, Inc. (NYSE:CATX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,602,283 shares of the company’s stock, valued at approximately $21,390,000. Perspective Therapeutics accounts for 17.6% of Nicholson Wealth Management Group LLC’s investment portfolio, making the stock its largest holding.

Several other institutional investors and hedge funds also recently modified their holdings of CATX. Bleakley Financial Group LLC acquired a new position in Perspective Therapeutics during the first quarter worth $40,000. nVerses Capital LLC acquired a new stake in Perspective Therapeutics during the third quarter worth approximately $57,000. Victory Capital Management Inc. bought a new stake in Perspective Therapeutics in the 2nd quarter valued at $117,000. Point72 DIFC Ltd acquired a new position in shares of Perspective Therapeutics in the second quarter valued at about $118,000. Finally, RIA Advisory Group LLC increased its holdings in shares of Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after purchasing an additional 99,293 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CATX. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. Oppenheimer reaffirmed an “outperform” rating and set a $22.00 price target on shares of Perspective Therapeutics in a report on Friday, October 11th. UBS Group started coverage on shares of Perspective Therapeutics in a research report on Thursday. They set a “buy” rating and a $20.00 price objective for the company. Finally, Bank of America assumed coverage on Perspective Therapeutics in a report on Thursday, July 25th. They issued a “buy” rating and a $24.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Perspective Therapeutics has an average rating of “Buy” and an average target price of $20.63.

Perspective Therapeutics Stock Up 1.7 %

Shares of NYSE:CATX opened at $11.89 on Friday. Perspective Therapeutics, Inc. has a one year low of $2.20 and a one year high of $19.05. The company has a 50 day moving average of $13.80.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. On average, research analysts forecast that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.